Status:
COMPLETED
A Study to Evaluate the Efficacy and Safety of AD-208
Lead Sponsor:
Addpharma Inc.
Conditions:
Androgenetic Alopecia
Eligibility:
MALE
18-50 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of AD-208.
Detailed Description
The purpose of this study is to evaluate the efficacy and safety of AD-208 in male patients with androgenetic alopecia.
Eligibility Criteria
Inclusion
- Male patients aged 18-50 years, inclusive
- Patients who meet the appropriate criteria according to the classification of hair loss
- Signed informed consent
Exclusion
- Patients with hair loss disorders other than androgenetic alopecia
- Other exclusions applied
Key Trial Info
Start Date :
June 9 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2023
Estimated Enrollment :
139 Patients enrolled
Trial Details
Trial ID
NCT04825561
Start Date
June 9 2021
End Date
June 1 2023
Last Update
July 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
Seoul, South Korea